|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Idelalisib and rituximab in relapsed chronic lympoeytic leukemia显示文摘 | Furman RR Sharman JP Coutre SE | 2014 | N Engl J Med2014，370，1： | 1 |
| 2 | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia显示文摘 | Byrd JC Furman RR Coutre SE | 2013 | N Engl J Med2013，369，1： | 1 |
| 3 | Targeting BTK withibrutinib in relapsed chronic lymphocytic leukemia显示文摘 | BYRD JC FURMAN RR COUTRE SE | 2013 | N Engl J财ed2013，369，1： | 1 |
| 4 | Ibrutinib as initialtherapy for elderly patients with chronic lymphocytic leukaemia orsmall lymphocytic lymphoma: an open-label, multicentre, phaselb/2 trial显示文摘 | O’BRIEN S FURMAN RR COUTRE SE | 2014 | Lancet Oncoi2014，15，1： | 1 |
| 5 | Phase I study of CAL-101,an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d,in patients with previously treated chronic lymphocytic leukemia显示文摘 | Coutre SE Byrd JC Furman RR | 2011 | Proc Am Soc Clin Oncol2011，，： | 1 |
| 6 | Targeting BTK with ibrutinib inrelapsed ehrtmic lymphocytic leukemia 显示文摘 | Byrd JC Furman RR Coutre SE | 2013 | N Engl J Med2013，369，1： | 1 |
| 7 | Ibrutinib as in-itial therapy for elderly patients with chronic lymphocytic leukae-mia or small lymphocytic lymphoma : an open-label, multicentre ,phase lb/2 trial显示文摘 | O'BRIEN S FURMAN RR COUTRE SE | 2014 | Lancet Oncol2014，15，1： | 1 |
| 8 | Ibmtinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, muhieentre, phase 1 b/2 trial 显示文摘 | O'Brien S Furman RR Coutre SE | 2014 | Lancet Oneol2014，15，1： | 1 |
| 9 | Idelalisib and rituximab in relapsed chronic lymphocytic leukemia显示文摘 | Furman RR Sharman JP Coutre SE | 2014 | N Engl J Med2014，370，： | 1 |
| 10 | The Bruton's tyro- sine kinase (BTK) inhibitor PCI-32765 (P) in treatment- naive (TN) chronic lymphocytic leu-kemia (CLL) patients (pts) : Interim results of a phase Ib/II study 显示文摘 | Byrd JC Furman RR Coutre SE | 2012 | J Clin Oncol2012，30，15： | 1 |
| 11 | Targeting Bruton tyrosine kinase with ibrutinib in relapsed chronic lymphocytic leukemia显示文摘 | Byrd JC Furman RR Coutre SE | 2013 | N Engl J Med2013，369，： | 1 |
| 12 | Targeting BTK with ibruti- nib in relapsed chronic lymphocytic leukemia 显示文摘 | Byrd JC Furman RR Coutre SE | 2013 | N Engl J Med2013，369，1： | 1 |
| 13 | Targeting 8TK with ibrutinib in relapsed chronic lymphocytic leukemia显示文摘 | Byrd JC Furman RR Coutre SE | 2013 | N Engl J Med2013，369，1： | 1 |
| 14 | Targeting Btk with ibrutinib in relapsed chronic lymphocytic leukemia显示文摘 | Byrd JC Furman RR Coutre SE | 2013 | N Engl J Med2013，369，1： | 1 |
| 15 | Acute myeloid leukemia 显示文摘 | O'DONNELL MR APPELBAUM FR COUTRE SE | 2008 | J Natl Compr Cane Netw2008，6，10： | 1 |
| 16 | Idelalisib, an inhibitor of phosphatidylinositol 3-kinase pl103, for relapsed/refractory chronic lymphocytic leukemia显示文摘 | Brown JR Byrd JC Coutre SE | 2014 | Blood2014，123，22： | 1 |
| 17 | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia显示文摘 | Byrd JC Furman RR Coutre SE | 2013 | N Engl J Med2013，369，1： | 1 |
| 18 | Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia显示文摘 | Byrd JC Furman RR Coutre SE | 2013 | N Engl J M ed2013，369，1： | 1 |
| 19 | Idelalisib,an inhibitor of phosphatidylinositol 3-kinase pl10δ,for relapsed/refractory chronic lymphocytic leukemia显示文摘 | Brown JR Byrd JC Coutre SE | 2014 | Blood2014，123，22： | 1 |
| 20 | Targeting BTK with ibrutinib in relapsed chronic lymphocytic lenkemia显示文摘 | Byrd JC Furman RR Coutre SE | 2013 | NEJM2013，369，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员